Chip Wilson, founder of Lululemon and an FSHD patient, sits down with Drs. Peter Jones and Charis Himeda to discuss his new $100 million venture, Solve FSHD, aimed at curing FSHD and age-related muscle decline.

Peter Jones answers recent patient questions and addresses issues relating to FSHD

Drs. Takako and Peter Jones discuss how they made the FLExDUX4 FSHD-like mouse model that is used around the world for FSHD therapeutic development and preclinical testing.

Free flowing commentary on all things FSHD

Dr. Julie Dumonceaux, Professor at University College London Great Ormond Street Institute of Child Health in London, England, discusses her lab's FSHD work and overall FSHD efforts in the UK with MyFSHD UK Ambassador Kate Fowles.

Dr. Charis Himeda joins us again to talk all types of FSHD therapeutic approaches

A primer on epigenetic gene and genome regulation and how it relates to FSHD

Dr. Alexandra Belayew from the University of Mons in Belgium and the discoverer of DUX4 sits down with volunteer MyFSHD Ambassador Jenny Hasenjaeger to discuss the discovery of DUX4, the Fulcrum Losmapimod trial, antisense, and a little bit of everything FSHD.

A short primer on the genetic differences and similarities between FSHD1, FSHD2, and FSHD1+2 just to make sure we are all up to speed.

Dr. Peter Jones sits down with Dr. Charis Himeda to discuss her invention of CRISPR-inhibition for FSHD, some of the bumps along the way, and its ultimate therapeutic potential and constraints.  In addition, other CRISPR technology that is being developed for FSHD is discussed.